title: Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1A/G1) in young women with polycystic ovarian syndrome.
abstract: BACKGROUND
  This report presents original, combined mode of treatment of preinvasive endometrial cancer (IA/G1) in young women with polycystic ovarian syndrome.
  
  
  OBJECTIVE
  The objective of the study was the assessment of treatment with natural female sexual hormones in combination with antidiabetic, antioxidative, antidopaminergic, and antiserotonin therapy on the concentrations of hormones and serotonin in blood serum in young women with polycystic ovary syndrome and preinvasive endometrial cancer.
  
  
  METHODS
  This study was performed within 12 months.
  
  
  METHODS
  The study was conducted in the Department of Menopause and Andropause of the Pomeranian Medical University in Szczecin, Poland. PARTICIPANTS AND STUDY DESIGN: Participants were 57 young PCOS women with concomitant preinvasive endometrial cancer (1A/G1). These women were 18–29 years old. They were treated with modified transdermal hormonal replacement therapy. Moreover, in permanent combined treatment, metformax 850 mg/d, bromcriptine mesylate 2.5 mg/d, and melatonin 5 mg/d were applied.
  
  
  METHODS
  Interventions in the study included blood sampling and dilation and curettage.
  
  
  METHODS
  The concentrations of gonadotropins, estrogens (estrone, 17-estradiol), progesterone, total/free T, and prolactin in basic conditions and after a metoclopramide stimulating test, dehydroepiandrosterone sulfate, and serotonin in blood serum were measured.
  
  
  RESULTS
  A significant increase in the concentrations of gonadotropins, estrogens, and progesterone was found. Moreover, the concentrations of androgens, prolactin, and serotonin were significantly decreased.
  
  
  CONCLUSIONS
  Micronized estradiol and progesterone in primary, preinvasive endometrial cancer (IA/G1) in young women, with polycystic ovarian syndrome with concomitant antidiabetic, antioxidative, antidopaminergic, and antiserotonin therapy, favorably influenced on the concentrations of female sexual hormones and lipid metabolism and caused the restoration of normal endometrium.
authors.affiliation: Department of Menopause and Andropause (S.S., J.v.M.-S., J.K.), Pomeranian Medical University, 70-204 Szczecin, Poland; and Department of Health Education (K.S.), Faculty of Health Culture and Health Promotion, University of Szczecin, 71-065 Szczecin, Poland.
authors.forename: Stanisław
authors.initials: S
authors.lastname: Stanosz
authors.forename: Jarosław
authors.initials: J
authors.lastname: von Mach-Szczypiński
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Sieja
authors.forename: Jakub
authors.initials: J
authors.lastname: Koœciuszkiewicz
mesh_terms: D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000150:complications* / Q000188:drug therapy*; D004717:Endometrium / Q000187:drug effects; D004958:Estradiol / Q000627:therapeutic use*; D004967:Estrogens / Q000378:metabolism; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use*; D012701:Serotonin / Q000097:blood; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D006728:Hormones; D012701:Serotonin; D011374:Progesterone; D004958:Estradiol